Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00759_DB00930_nanopub.RAE0tw6v923yszjw_VW1KemL1zwv7hSnhcIeAqxMbhrCc#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00759_DB00930 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00759_DB00930 label "DDI between Tetracycline and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam. [drugbank_resource:DB00759_DB00930]" assertion.
- drugbank_resource:DB00759_DB00930 identifier "drugbank_resource:DB00759_DB00930" assertion.
- drugbank_resource:DB00759_DB00930 title "DDI between Tetracycline and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam." assertion.
- drugbank:DB00759 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00759_DB00930 assertion.
- drugbank:DB00930 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00759_DB00930 assertion.